Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 15/20 | 0.63 |
| ▸ | MMP9 | P14780 | 6/20 | 0.63 |
| ▸ | MMP1 | P03956 | 9/20 | 0.59 |
| ▸ | MMP3 | P08254 | 9/20 | 0.59 |
| ▸ | MMP13 | P45452 | 7/20 | 0.59 |
| ▸ | MMP7 | P09237 | 6/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795511 | 0.91 | CA12 (0.57) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7795549 | 0.91 | MMP2 (0.51) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7802317 | 0.85 | MMP1 (0.67) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7803686 | 0.82 | MMP1 (0.70) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7805677 | 0.79 | MMP1 (0.65) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7804372 | 0.78 | KMT2A (0.44) | MMP2MMP9 | |
| SCHEMBL6394072 | 0.76 | MMP1 (0.76) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7804336 | 0.76 | CA12 (0.62) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7802263 | 0.76 | MMP1 (0.58) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7349862 | 0.74 | MMP1 (0.91) | MMP2MMP9MMP1MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010056184-A1 | Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056184-A1 | Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds | NCEH1, NOP10, HRH1 | MMP2 4208/4885MMP9 4090/4885MMP1 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.